鹭燕医药
(002788)
| 流通市值：34.13亿 | | | 总市值：34.85亿 |
| 流通股本：3.80亿 | | | 总股本：3.89亿 |
| 报告期 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 5,135,680,997.86 | 19,845,534,615.24 | 14,775,163,931.09 | 10,024,249,628.07 |
| 营业收入 | 5,135,680,997.86 | 19,845,534,615.24 | 14,775,163,931.09 | 10,024,249,628.07 |
| 二、营业总成本 | 5,015,345,024.95 | 19,359,450,781.01 | 14,436,462,358.36 | 9,784,261,876.82 |
| 营业成本 | 4,757,525,388.33 | 18,336,470,188.47 | 13,687,313,351.76 | 9,281,898,532.66 |
| 税金及附加 | 11,037,807.51 | 43,549,511.38 | 30,156,025.94 | 19,856,817.96 |
| 销售费用 | 114,820,698.65 | 441,712,880 | 325,351,295.64 | 218,382,883.09 |
| 管理费用 | 78,011,484.36 | 309,275,092.96 | 223,741,639.55 | 151,490,029.68 |
| 研发费用 | 1,217,913.27 | 5,534,269.41 | 2,835,211.85 | 1,938,212.92 |
| 财务费用 | 52,731,732.83 | 222,908,838.79 | 167,064,833.62 | 110,695,400.51 |
| 其中:利息费用 | 50,776,018.56 | 222,852,936.19 | 150,996,843.31 | 101,437,599.57 |
| 其中:利息收入 | 1,040,779.9 | 5,142,020.27 | 3,655,873.98 | 3,750,347.37 |
| 加:公允价值变动收益 | 0 | - | - | - |
| 加:投资收益 | -3,551,142.87 | -12,155,845.85 | -4,851,615.76 | -1,664,819.49 |
| 净敞口套期收益 | 0 | - | - | - |
| 资产处置收益 | -3,612.5 | 275,980.87 | -116,290.43 | -151,558.88 |
| 资产减值损失(新) | -575,385.33 | -2,580,405.71 | -579,622.77 | -328,601.49 |
| 信用减值损失(新) | -12,280,456.9 | -14,714,043.7 | -18,282,400.98 | -10,937,885.18 |
| 其他收益 | 1,595,980.44 | 11,646,956.64 | 7,575,040.79 | 5,577,202.45 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 105,521,355.75 | 468,556,476.48 | 322,446,683.58 | 232,482,088.66 |
| 加:营业外收入 | 246,552.02 | 2,652,324.38 | 1,227,111.09 | 1,167,601.26 |
| 减:营业外支出 | 227,063.14 | 1,787,077.39 | 932,762.63 | 651,055.79 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 105,540,844.63 | 469,421,723.47 | 322,741,032.04 | 232,998,634.13 |
| 减:所得税费用 | 22,016,434.91 | 104,927,350.84 | 63,681,716.75 | 42,902,743.03 |
| 六、净利润 | 83,524,409.72 | 364,494,372.63 | 259,059,315.29 | 190,095,891.1 |
| 持续经营净利润 | 83,524,409.72 | 364,494,372.63 | 259,059,315.29 | 190,095,891.1 |
| 归属于母公司股东的净利润 | 83,776,431.42 | 363,530,313.01 | 261,975,916.42 | 189,013,659.46 |
| 少数股东损益 | -252,021.7 | 964,059.62 | -2,916,601.13 | 1,082,231.64 |
| (一)基本每股收益 | 0.22 | 0.94 | 0.67 | 0.49 |
| 八、其他综合收益 | 5,174.94 | 1,017,731.35 | 1,216,025.57 | 1,335,862.82 |
| 归属于母公司股东的其他综合收益 | 5,174.94 | 1,017,731.35 | 1,216,025.57 | 1,335,862.82 |
| 九、综合收益总额 | 83,529,584.66 | 365,512,103.98 | 260,275,340.86 | 191,431,753.92 |
| 归属于母公司股东的综合收益总额 | 83,781,606.36 | 364,548,044.36 | 263,191,941.99 | 190,349,522.28 |
| 归属于少数股东的综合收益总额 | -252,021.7 | 964,059.62 | -2,916,601.13 | 1,082,231.64 |
| 公告日期 | 2024-04-16 | 2024-04-16 | 2023-10-24 | 2023-08-08 |
| 审计意见(境内) | | 标准无保留意见 | | |